Anthera jumps 25% on blisibimod update, new endpoint
This article was originally published in Scrip
Executive Summary
Hayward, California-based Anthera Pharmaceuticals jumped 25% to close at $3.25 per share on 10 February after the company said an independent statistician recommended continuation of a Phase III lupus clinical trial for blisibimod following an interim analysis based on the trial's new primary endpoint.
You may also be interested in...
After Bad Data Comes Layoffs – Will The Next Job Cuts Be At Anthera?
Anthera is exploring strategic alternatives after its lead drug candidate Sollpura failed in Phase III, which means layoffs may be coming soon. Several other biopharma companies have had to turn to job cuts already this year.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.